Agios Pharmaceuticals (AGIO) announced that the U.S. Food and Drug Administration, FDA, has extended the Prescription Drug User Fee Act, PDUFA, goal date for the supplemental New Drug Application, sNDA, of PYRUKYND, an oral pyruvate kinase activator, for the treatment of adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia by three months to December 7, 2025. Following a recent information request from the FDA, Agios submitted a proposed Risk Evaluation and Mitigation Strategy, REMS, to mitigate the risk of hepatocellular injury that was described in the original PYRUKYND sNDA. The submission of the REMS is a major amendment to the PYRUKYND sNDA, resulting in a three-month review extension. This extension is not the result of new or additional efficacy or safety data requested by the FDA or submitted by Agios. “We remain confident in the favorable benefit-risk profile of PYRUKYND in thalassemia,” said Brian Goff, Chief Executive Officer, Agios. “We look forward to continuing our collaborative engagement with the FDA, with the goal of bringing this disease-modifying oral medicine to adult patients with thalassemia in the U.S.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGIO:
- Positive Outlook for Agios Pharma Despite Recent Patient Deaths Unrelated to Pyrukynd Treatment
- Agios Pharmaceuticals reports Pyrukynd approval by Saudi Food and Drug Authority
- Agios Pharma’s PYRUKYND Approved by Saudi Authority
- Leerink says Agios pressure related to deaths listed in FAERS database
- Agios evaluating fourth Pyrukynd case after analyst report